Understanding the VRd Regimen for Newly Diagnosed Myeloma

The “triplet” (3-drug) combination of Velcade® (bortezomib) + Revlimid® (lenalidomide) + dexamethasone [VRd] is a highly effective and well-tolerated therapy for patients with newly diagnosed multiple myeloma (NDMM). Each drug has a different way of attacking myeloma, and each enhances the activity of the other drugs in this combination therapy. Currently, while VRd is still used in some regions, research data continues to emerge in support of “quadruplet” (4-drug) therapies of VRd plus a fourth drug.